Overcoming the Dilemma of First-line TKI Resistance: Olverembatinib Second-line Treatment Achieves 76% CCyR in CP-CML without T315I Mutation

Overcoming the Dilemma of First-line TKI Resistance: Olverembatinib Second-line Treatment Achieves 76% CCyR in CP-CML without T315I Mutation

The treatment of Chronic Myeloid Leukemia (CML) has entered the era of Tyrosine Kinase Inhibitors (TKIs), but the choice of treatment for patients after the failure of first-line therapy remains a focus of clinical attention. Olverembatinib (HQP1351), as the first third-generation TKI independently developed in China, has previously demonstrated excellent efficacy in populations carrying the T315I mutation. However, what is the value of Olverembatinib for patients in the chronic phase (CP-CML) who do not carry the T315I mutation and have developed resistance or intolerance after first-line TKI therapy? At a recent academic conference, Professor Li Weiming from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology shared the latest efficacy and safety data of Olverembatinib in the second-line treatment of CP-CML patients. This article is specially organized for readers.
EHA Highlights | Professor Zhang Xian: Largest-Ever Cohort of 171 Patients Reinforces the Potential of NS7 CAR-T in Tackling Relapsed/Refractory T-ALL/LBL

EHA Highlights | Professor Zhang Xian: Largest-Ever Cohort of 171 Patients Reinforces the Potential of NS7 CAR-T in Tackling Relapsed/Refractory T-ALL/LBL

Relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) carries an extremely poor prognosis, with long-term survival rates of only 10%–20%. The advent of NS7 CAR-T, a novel naturally selected CD7-directed CAR-T therapy that requires no additional genetic modification, has brought a transformative breakthrough to the treatment of these diseases.
EHA Echoes | Prof. Wenming Chen: Advancing Plasma Cell Disease Treatment Through Clinical Innovation and Translational Research with Aponermin-Based Combination Therapies

EHA Echoes | Prof. Wenming Chen: Advancing Plasma Cell Disease Treatment Through Clinical Innovation and Translational Research with Aponermin-Based Combination Therapies

At the 2026 Congress of the European Hematology Association (EHA), innovative research from Chinese investigators in the field of multiple myeloma attracted significant attention. The team led by Prof. Wenming Chen from Beijing Chaoyang Hospital, Capital Medical University, presented a series of studies evaluating aponermin (Aponermin)-based combination therapies for multiple myeloma, plasmacytoma, and plasma cell leukemia.
EHA Echoes | Prof. Liang Wang: CD19/CD22 Dual-Target CAR-T Plus  Maintenance Therapy Breaks Through the Long-Term Survival Bottleneck in R/R LBCL

EHA Echoes | Prof. Liang Wang: CD19/CD22 Dual-Target CAR-T Plus  Maintenance Therapy Breaks Through the Long-Term Survival Bottleneck in R/R LBCL

At the 2026 Congress of the European Hematology Association (EHA), Prof. Liang Wang from Beijing Tongren Hospital, Capital Medical University, delivered an oral presentation unveiling the latest follow-up results of CAR2219, a CD19/CD22 dual-target CAR-T cell therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The study reported an impressive 12-month progression-free survival (PFS) rate of 59.8%.
EHA Echoes from Stockholm | Professor Bing Han: Phase III ESLIM-02 Trial Meets Primary Endpoint, Sovleplenib Poised to Reshape the Treatment Landscape of Warm Autoimmune Hemolytic Anemia

EHA Echoes from Stockholm | Professor Bing Han: Phase III ESLIM-02 Trial Meets Primary Endpoint, Sovleplenib Poised to Reshape the Treatment Landscape of Warm Autoimmune Hemolytic Anemia

Patients with warm autoimmune hemolytic anemia (wAIHA) have long faced a significant lack of effective second-line treatment options, often becoming trapped in a cycle of corticosteroid dependence and recurrent disease relapse. At the 2026 European Hematology Association (EHA) Congress, Professor Bing Han of Peking Union Medical College Hospital presented the pivotal results of the Phase III ESLIM-02 trial evaluating sovleplenib in wAIHA. The study represents a major breakthrough in a field that has historically lacked targeted therapies and offers new hope for convenient outpatient management of this chronic autoimmune disorder.
Science Without Borders, Advancing Toward Cure: EHA 2026 Opens in Stockholm, Charting a New Era of Global Collaboration and High-Quality Development in Hematology

Science Without Borders, Advancing Toward Cure: EHA 2026 Opens in Stockholm, Charting a New Era of Global Collaboration and High-Quality Development in Hematology

In June 2026, the European Hematology Association (EHA) Congress officially opened in Stockholm, Sweden, bringing together the global hematology community for one of the field’s most influential scientific events. As the largest and most prestigious annual meeting in hematology, EHA 2026 not only showcased groundbreaking scientific discoveries but also unveiled strategic initiatives that will help shape the future of hematology research and patient care over the next decade.
EHA 2026 Echoes | Hui Wang and Man Chen: Impact of Two Antithymocyte Globulin Conditioning Regimens on Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation

EHA 2026 Echoes | Hui Wang and Man Chen: Impact of Two Antithymocyte Globulin Conditioning Regimens on Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation

The 2026 Congress of the European Hematology Association (EHA 2026), held from June 11–14 in Stockholm, Sweden, brought together leading experts from around the world to showcase the latest advances in hematology research, translational medicine, and clinical practice.
EHA 2026 Echoes | Qian Jiang: Addressing Both Ends of the CML Spectrum—Advancing Precision Therapy and the New Era of Treatment-Free Remission

EHA 2026 Echoes | Qian Jiang: Addressing Both Ends of the CML Spectrum—Advancing Precision Therapy and the New Era of Treatment-Free Remission

At the 2026 Congress of the European Hematology Association (EHA 2026), the team led by Professor Qian Jiang from Peking University People’s Hospital presented several important studies addressing key challenges in chronic myeloid leukemia (CML), including the biological heterogeneity of accelerated-phase disease and predictors of treatment-free remission (TFR).
EHA 2026 Echoes | Ruijuan Sun and Hai He: Allogeneic HSCT Overcomes the Poor Prognosis Associated with NUP98::NSD1-Positive Acute Myeloid Leukemia

EHA 2026 Echoes | Ruijuan Sun and Hai He: Allogeneic HSCT Overcomes the Poor Prognosis Associated with NUP98::NSD1-Positive Acute Myeloid Leukemia

The 2026 Congress of the European Hematology Association (EHA 2026) was held from June 11 to 14 in Stockholm, Sweden. As one of the most influential international meetings in hematology, EHA brings together leading experts from around the world to showcase the latest advances in basic science, translational research, and clinical practice.